文献速递外周动脉疾病

CYP2C19基因多态性与严重肢体缺血EVT术后氯吡格雷治疗截肢率相关

CYP2C19 Polymorphism is Associated With Amputation Rates in Patients Taking Clopidogrel After Endovascular Intervention for Critical Limb Ischaemia.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2019-08-05

本研究回顾性纳入278例严重肢体缺血(CLI)行血管内治疗(EVT)后仅服用氯吡格雷的患者,按CYP2C19功能缺失等位基因分为快代谢型(EM)、中间代谢型(IM)和慢代谢型(PM)。结果显示,携带至少一个功能缺失等位基因者血小板反应性更高,12个月无截肢生存率和总生存率显著降低,多因素分析证实IM+PM组合与无截肢生存率及总死亡率独立相关。

要点

  • CYP2C19功能缺失等位基因携带者服用氯吡格雷后血小板反应性更高。
  • IM和PM组12个月无截肢生存率及总生存率显著低于EM组。
  • IM+PM组合是无截肢生存率和总死亡率的独立危险因素。

核心结论

  • CYP2C19基因型可显著影响CLI患者EVT术后仅服用氯吡格雷的无截肢生存率和总死亡率。

研究设计与样本

  • 回顾性研究纳入2014年8月至2017年1月期间接受EVT的278例CLI患者,按CYP2C19功能缺失等位基因分为EM(153例)、IM(79例)和PM(46例)三组。

临床怎么用

  • 对EVT术后仅使用氯吡格雷的CLI患者,可考虑进行CYP2C19基因检测以识别高截肢和死亡风险者。
  • 对CYP2C19中间代谢型或慢代谢型患者,需加强监测或考虑替代抗血小板策略。

局限性

  • 本研究为回顾性设计,仅278例患者完成12个月随访检查(180/278,64.7%),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clopidogrel is a pro-drug requiring cytochrome P450 (CYP) 2C19 enzyme to be oxidised to its active form. This study evaluated the association between the CYP 2C19 genetic polymorphism and clinical outcomes in patients with critical limb ischaemia (CLI) taking clopidogrel after endovascular therapy (EVT). METHODS: This was a retrospective study. Patients with CLI who had undergone EVT between August 2014 and January 2017 were included. The study subjects were divided into three groups according to the loss of function (LOF) CYP2C19 alleles: (1) extensive metaboliser (EM); (2) intermediate metaboliser (IM); and (3) poor metaboliser (PM). All patients underwent a platelet function test (VerifyNow). Amputation free survival and all cause mortality were estimated using the Kaplan-Meier method. The association between baseline characteristics and clinical outcomes was assessed with the Cox proportional hazard model. RESULTS: A total of 278 CLI patients (EM: 153, IM: 79, PM: 46) who underwent EVT were included. There were 180/278 (64.7%, EM: 107, IM: 45, PM: 28) patients who completed the 12 month follow up examination. Carriers of at least one CYP2C19 LOF allele (44.9%, 125/278) had diminished pharmacodynamic responses to clopidogrel as measured using VerifyNow (174 ± 27 platelet reactivity units (PRU), 216 ± 21 PRU, and 245 ± 35 PRU for patients with EM, IM, and PM CYP2C19 profiles, respectively; EM vs. IM, p < .0001 and EM vs. PM, p < .0001). The estimated amputation free 12 month survival rates were EM 82.1%, IM 66.1.0%, and PM 56.6% with significant differences between groups (log-rank test p = .0006, p for trend <.0001). The estimated all cause 12 month mortality rates were EM 83.7%, IM 72.2%, and PM 71.3% (log rank test p = .01, p for trend p = .007). The combined group consisting of IM and PM was associated with amputation free survival and all cause mortality based on a univariable analysis (hazard ratio [HR] = 2.23 [1.97-2.46], p = .011; HR = 1.43 [1.05-1.85], p = .043) and remained significant in a multivariable Cox analysis (HR = 2.65 [2.1-2.9], p = .009; HR = 1.39 [1.07-1.74], p = .037). CONCLUSION: CYP2C19 genetic profiles can significantly influence clinical outcomes (in both amputation free survival and all cause mortality) in CLI patients who are taking only clopidogrel after EVT.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Lee J, Cheng N, Tai H, et al. CYP2C19 Polymorphism is Associated With Amputation Rates in Patients Taking Clopidogrel After Endovascular Intervention for Critical Limb Ischaemia. Eur J Vasc Endovasc Surg. 2019. PMID: 31395432. doi:10.1016/j.ejvs.2019.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。